DIRECT ISSUE 2024
Stayble Therapeutics AB has carried out a directed issue of a total of 4,000,000 units, where each unit consists of three newly issued shares and two warrants of series TO2 in the Company, corresponding to a total of 12,000,000 shares and 8,000,000 warrants of series TO2.
Through the direct issue, the Company was thus provided with approximately three million kroner before deductions for transaction costs, and in the event that all the attached warrants of series TO2 are used for the subscription of shares in the Company, the Company will, depending on the subscription price upon exercise of the warrants, be provided with approximately two more to three million kroner before deductions for transaction costs.
For more information, see the following link (in Swedish):
https://staybletherapeutics.com/sv/investerare/riktad-emission-2024/
